Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Dawson, Sarah"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Todd, John A., Evangelou, Marina, Cutler, Antony J., Pekalski, Marcin L., Walker, Neil M., Stevens, Helen E., Porter, Linsey, Smyth, Deborah J., Rainbow, Daniel B., Ferreira, Ricardo C., Esposito, Laura, Hunter, Kara M. D., Loudon, Kevin, Irons, Kathryn, Yang, Jennie H., Bell, Charles J. M., Schuilenburg, Helen, Heywood, James, Challis, Ben, Neupane, Sankalpa, Clarke, Pamela, Coleman, Gillian, Dawson, Sarah, Goymer, Donna, Anselmiova, Katerina, Kennet, Jane, Brown, Judy, Caddy, Sarah L., Lu, Jia, Greatorex, Jane, Goodfellow, Ian, Wallace, Chris, Tree, Tim I., Evans, Mark, Mander, Adrian P., Bond, Simon, Wicker, Linda S., Waldron-Lynch, Frank
Publikováno v:
PLoS Medicine
PLoS Medicine, Vol 13, Iss 10, p e1002139 (2016)
Todd, J A, Evangelou, M, Cutler, A J, Pekalski, M L, Walker, N M, Stevens, H E, Porter, L, Smyth, D J, Rainbow, D B, Ferreira, R C, Esposito, L, Hunter, K M D, Loudon, K, Irons, K, Yang, J H, Bell, C J M, Schuilenburg, H, Heywood, J, Challis, B, Neupane, S, Clarke, P, Coleman, G, Dawson, S, Goymer, D, Anselmiova, K, Kennet, J, Brown, J, Caddy, S L, Lu, J, Greatorex, J, Goodfellow, I, Wallace, C, Tree, T I, Evans, M, Mander, A P, Bond, S, Wicker, L S & Waldron-Lynch, F 2016, ' Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2 : A Non-Randomised, Open Label, Adaptive Dose-Finding Trial ', PL o S Medicine, vol. 13, no. 10, e1002139 . https://doi.org/10.1371/journal.pmed.1002139
PLoS Medicine, Vol 13, Iss 10, p e1002139 (2016)
Todd, J A, Evangelou, M, Cutler, A J, Pekalski, M L, Walker, N M, Stevens, H E, Porter, L, Smyth, D J, Rainbow, D B, Ferreira, R C, Esposito, L, Hunter, K M D, Loudon, K, Irons, K, Yang, J H, Bell, C J M, Schuilenburg, H, Heywood, J, Challis, B, Neupane, S, Clarke, P, Coleman, G, Dawson, S, Goymer, D, Anselmiova, K, Kennet, J, Brown, J, Caddy, S L, Lu, J, Greatorex, J, Goodfellow, I, Wallace, C, Tree, T I, Evans, M, Mander, A P, Bond, S, Wicker, L S & Waldron-Lynch, F 2016, ' Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2 : A Non-Randomised, Open Label, Adaptive Dose-Finding Trial ', PL o S Medicine, vol. 13, no. 10, e1002139 . https://doi.org/10.1371/journal.pmed.1002139
Background Interleukin-2 (IL-2) has an essential role in the expansion and function of CD4+ regulatory T cells (Tregs). Tregs reduce tissue damage by limiting the immune response following infection and regulate autoreactive CD4+ effector T cells (Te
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::e1c8df238f9bd0b4b509e1bf7c865862
https://ora.ox.ac.uk/objects/uuid:01a52af1-ff42-4256-99be-80df2bfa4ad6
https://ora.ox.ac.uk/objects/uuid:01a52af1-ff42-4256-99be-80df2bfa4ad6
Autor:
Dawson, Sarah-Jane1,2,3, Tsui, Dana W. Y.1, Murtaza, Muharnmed1, Biggs, Heather2, Rueda, Oscar M.1, Suet-Feung Chin1, Dunning, Mark J.1, Gale, Davina1, Forshew, Tim1, Mahler-Araujo, Betania2,4, Rajan, Sabrina2,5, Hurnphray, Sean6, Becq, Jennifer6, Halsall, David7, Wallis, Matthew2,5, Bentley, David6, Caldas, Carlos1,2,8 carlos.caldas@cruk.cam.ac.uk, Rosenfeld, Nitzan1
Publikováno v:
New England Journal of Medicine. 3/28/2013, Vol. 368 Issue 13, p1199-1209. 11p.
Autor:
Carlton, Henry C.1 (AUTHOR) Henryccarlton@gmail.com, Savović, Jelena1,2 (AUTHOR), Dawson, Sarah1,2 (AUTHOR), Mitchelmore, Philip J.3,4 (AUTHOR), Elwenspoek, Martha M.C.1,2 (AUTHOR)
Publikováno v:
Clinical Microbiology & Infection. Aug2021, Vol. 27 Issue 8, p1096-1108. 13p.
Autor:
Todd, John A, Evangelou, Marina, Cutler, Antony J, Pekalski, Marcin L, Walker, Neil M, Stevens, Helen E, Porter, Linsey, Smyth, Deborah J, Rainbow, Daniel B, Ferreira, Ricardo C, Esposito, Laura, Hunter, Kara MD, Loudon, Kevin, Irons, Kathryn, Yang, Jennie H, Bell, Charles JM, Schuilenburg, Helen, Heywood, James, Challis, Ben, Neupane, Sankalpa, Clarke, Pamela, Coleman, Gillian, Dawson, Sarah, Goymer, Donna, Anselmiova, Katerina, Kennet, Jane, Brown, Judy, Caddy, Sarah L, Lu, Jia, Greatorex, Jane, Goodfellow, Ian, Wallace, Chris, Tree, Tim I, Evans, Mark, Mander, Adrian P, Bond, Simon, Wicker, Linda S, Waldron-Lynch, Frank
BACKGROUND: Interleukin-2 (IL-2) has an essential role in the expansion and function of CD4+ regulatory T cells (Tregs). Tregs reduce tissue damage by limiting the immune response following infection and regulate autoreactive CD4+ effector T cells (T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5116d1b5807968bbe212eda6d0abd7e8
Autor:
Salvatore Grisanti, Tanja Fehm, Daniele Generali, Jean-Yves Pierga, Dimitrios Mavroudis, Mario Giuliano, Leticia De Mattos-Arruda, Steven Van Laere, Lorenzo Gerratana, Francesca Consoli, Wolfgang Janni, Klaus Pantel, Luc Dirix, Stefan Michiels, Carlos Caldas, Annemie Rutten, Jorge S. Reis-Filho, Michail Ignatiadis, Dieter Peeters, Andrew M. Davis, Sarah-Jane Dawson, Jose Vidal-Martinez, Cristina Raimondi, Massimo Cristofanilli, Alfred Rademaker, Maria Teresa Sandri, Justin Stebbing, Rita Zamarchi, Franziska Meier-Stiegen, Elisabetta Munzone, Jonathan Krell, Vicente Carañana, Erich-Franz Solomayer, Laura Zorzino, Franco Nolè, Paola Gazzaniga, Eduardo Díaz-Rubio, Lauren Darrigues, Luc Cabel, Rafael Gisbert-Criado, Eleni Politaki, Sofia Agelaki, José A. García-Sáenz, Angela Fernandez de Lascoiti, Maria Rosa Cappelletti, Camillo Almici, Luis Manso, François-Clément Bidard, James M. Reuben
Publikováno v:
Critical reviews in oncology, hematology
Background: The heterogeneity of metastatic breast cancer (MBC) necessitates novel biomarkers allowing stratification of patients for treatment selection and drug development. We propose to use the prognostic utility of circulating tumor cells (CTCs)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39ef4c527220afcd22fd71cd8f94b62a
https://hdl.handle.net/11368/2935442
https://hdl.handle.net/11368/2935442